United States: Doryx: Third Circuit Affirms Dismissal Of Product Hopping Claim

On September 28, 2016, in Mylan Pharmaceuticals Inc. v. Warner Chilcott Public Limited Co. (Doryx), the Third Circuit affirmed the lower court's grant of summary judgment against antitrust claims by generic manufacturer Mylan regarding branded manufacturer Warner Chilcott's alleged "product hopping" activity with respect to its drug Doryx (delayed-release doxycycline hyclate). The court distinguished other product hopping cases—including the recent Second Circuit decision in Namenda—and held that Mylan failed to put forth sufficient evidence that Warner Chilcott possessed monopoly power or engaged in anticompetitive conduct. WilmerHale had filed an amicus brief supporting the defendants.


Product hopping claims arise from line extension strategies that are a staple of pharmaceutical life cycle management plans. With its legacy Product A facing generic competition, a branded drug manufacturer launches a next-generation Product B. This new drug might incorporate formulation changes, dosage modifications, or other alterations that may improve safety, efficacy or convenience of the product. Because the generic version of Product A will not be "AB rated" to Product B, under the generic substitution laws of many states, pharmacists are unable to automatically substitute generic versions of Product A when presented with a prescription for Product B. Generic Product A is still available to consumers, but they or their physicians must affirmatively request it.

In Doryx, Mylan alleged that Warner Chilcott's sequential product improvements to its acne drug Doryx violated the Sherman Act. Plaintiff's case centered on four alleged "hops": first, a change from 75 mg and 100 mg capsules to 75 mg and 100 mg tablets, then to a single-scored 150 mg tablet, then to adding score lines to 75 mg and 100 mg tablets, and finally from a single- to a dual-scored 150 mg tablet. Mylan alleged that these changes illegally excluded its generic product from the market "because Mylan's generic would not automatically be substituted [under state substitution laws] unless Mylan redesigned the generic to match the new version of Doryx and secured an AB-rating from the FDA."

On summary judgment, the district court found that Mylan failed to raise an issue of fact as to whether Warner Chilcott possessed monopoly power in the relevant market. The court rejected Mylan's narrow view of the market—branded and generic Doryx—and embraced Warner Chilcott's view that the market consisted of all oral tetracyclines prescribed to treat acne. Warner Chilcott's share of that broader market was insufficient to support an inference of monopoly power.

As an additional basis for granting summary judgment, the district court found that there was no question of fact in terms of whether Warner Chilcott's hops constituted exclusionary conduct. Warner Chilcott's reformulations had not harmed competition because "doctors remained free to prescribe generic Doryx; pharmacists remained free to substitute generics when medically appropriate; and patients remained free to ask their doctors and pharmacists for generic versions of the drug." That sales through automatic substitution are less costly to the generic competitors was irrelevant according to the district court. Mylan decided not to promote its product, and could not "transform its own refusal to incur promotional costs into defendants' anticompetitive conduct."


The Third Circuit examined both the issue of monopoly power and whether Warner Chilcott's product hops were anticompetitive, and affirmed the lower court on both fronts.

The court framed the monopoly power inquiry as "whether the relevant market consists only of the defendants' product and the plaintiff's product, or whether the market comprises third-party products as well." It found that evidence that Warner Chilcott might have realized profit margins as high as 83 percent was, standing alone, insufficient to support a finding of monopoly power. Instead, the court undertook a more traditional relevant market analysis. Looking first to interchangeability, the court held that Doryx was interchangeable with oral tetracyclines other than generic Doryx. This was supported, the court held, by the opinions of dermatologists, the fact that the FDA approved nearly identical labeling for Doryx and other oral tetracyclines, and health insurers' frequent encouragement of substitution of other, less costly oral tetracyclines for Doryx. Turning to cross-elasticity of demand (a measure of the degree to which products are substitutable from buyers' point of view), the court highlighted Warner Chilcott's unrebutted expert testimony that demand for other oral tetracyclines responded to Warner Chilcott's marketing and sales decisions; e.g., when Warner Chilcott increased the price of branded Doryx, sales of other tetracyclines increased. The Third Circuit affirmed the district court's broad definition of the relevant market based on these two factors, and agreed that Warner Chilcott's share of that market—only 18 percent—was too low to suggest monopoly power.

The Third Circuit also affirmed the district court's finding that Warner Chilcott's product hopping strategy was not anticompetitive. Notably, the court applied the Section 2 rule of reason analysis from United States v. Microsoft, 253 F.3d 34 (D.C. Cir. 2000) (en banc). Under the first part of that analysis, the court found that Warner Chilcott's product changes were not anticompetitive because Mylan was not foreclosed from the market. Mylan never manufactured a capsule version of generic Doryx during the 20 years that branded Doryx capsules were on the market (although it could have), and when Mylan did develop a tablet version of the updated Doryx product, it received 180 days of exclusive rights over generic versions (which gave it strong incentives to go to market). Mylan's $146.9 million in profits on generic doxycycline hyclate belied its assertions that it was the victim of anticompetitive conduct, the court held. Moreover, even assuming that Mylan had introduced some evidence of anticompetitive effects, the Third Circuit observed that there was evidence of procompetitive purposes for Warner Chilcott's product changes. These included addressing safety concerns and shelf-life problems with the capsule version of the product, a need to compete with generics that offered the product in different dosages, and the patient benefits of scored tablets.

Importantly, the Third Circuit distinguished the Second Circuit's 2015 decision in Namenda, another product hopping case. In Namenda, the Second Circuit affirmed the lower court's grant of a preliminary injunction where a branded manufacturer reformulated an Alzheimer's drug as patent protection expired, and then limited distribution of the legacy product. The Third Circuit held that Namenda was factually and procedurally distinct. Whereas Namenda involved a branded manufacturer's attempt to avoid the usual loss of market share that accompanies patent expiration "by stringing together new periods of patent exclusivity in order to completely bar generics from entering the market," in Doryx Warner Chilcott did not face a "patent cliff" and generic manufacturers had already entered the market by the time of the allegedly anticompetitive conduct. The Third Circuit also observed that Namenda was procedurally different—the Second Circuit had reviewed the grant of a preliminary injunction, whereas the Third Circuit was reviewing a lower court's summary judgment decision on "a robust record void of any evidence of anticompetitive conduct."


The Third Circuit's Doryx decision is one of only a handful of decisions in the developing body of antitrust law concerning product hopping. It marks only the second appellate court decision on the issue, and the first to hold that the alleged activity did not violate the antitrust laws. Although the decision is closely tied to the particular facts of the case, it nonetheless signals that Namenda may not be expanded to find all product hopping activity essentially illegal per se, and that courts will examine closely whether generic manufacturers truly are "excluded"—as opposed to merely being unable to take full advantage of state substitution laws—and whether the challenged hopping brings procompetitive benefits. The case also has important implications for how courts define the relevant antitrust market in pharmaceutical cases, and will stand as a key precedent rejecting a claim (which antitrust plaintiffs often advance) that each drug or molecule constitutes a unique market.

At a broader level, Doryx illustrates a crucial point in product hopping and other controversial areas of monopolization law: theory is important, but the case-specific facts matter greatly. Accordingly, when contemplating conduct that may raise claims of exclusion, pharmaceutical and other firms are well advised to ask the following questions: Does the firm have a dominant position in the product at issue? Does the conduct at issue have significant potential to impair a rival on some basis other than competition on the merits (e.g., lower prices or better quality), and if so, are there procompetitive benefits from the conduct that outweigh any possible harm to competition?

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.